Navigation Links
A longer lasting tumor blocker
Date:4/28/2009

On the heels of dismaying reports that a promising antitumor drug could, in theory, shorten patients' long-term survival, comes a promising study by a Japanese team of researchers that suggests a potentially better option. The study appears in the May 11 issue of the Journal of Experimental Medicine (online April 27).

Many cancer treatments work by disrupting the formation of new blood vessels that feed growing tumors. Agents that block a vessel-promoting factor called VEGF have shown promise in human clinical trials. But recent studies in mice show that when treatment stops, tumor growth rapidly resumes. Now, Yoshiaki Kubota and colleagues find that blocking a different molecule, called M-CSF, suppressed tumor growth even after treatment was stopped.

Kubota and his team compared the efficacy of inhibitors against M-CSF and VEGF in mice with a certain kind of bone tumor. Three weeks of anti-VEGF treatment suppressed tumor growth but, similar to other recent reports, the tumors bounced back when the drug treatment was curtailed. Tumor growth in mice on a similar regiment of an M-CSF inhibitor remained suppressed in the absence of drug.

Another distinction between the two inhibitors was the type of vessel growth that was blocked. Blocking VEGF prevented dangerous vessels from growing such as those that feed tumors. But it also stopped beneficial vessels from growing, such as those that help injured tissues heal. Blocking M-CSF, on the other hand, only impeded bad vessel growth.

Most likely, the antiM-CSF treatment had a lasting effect because it resulted in damage to the scaffolding that surrounds cancerous vessels, robbing the tumors of the structural support they need to grow. Meanwhile, the scaffold of mice treated with anti-VEGF remained intact.

M-CSF levels soar in patients with osteosarcoma (a malignant bone cancer), breast cancer and prostate cancer, making these cancers potentially the most responsive to M-CSF-blocking drugs Whether or not other types of cancer rely more on M-CSF than on VEGF for their blood supply remains unknown.


'/>"/>

Contact: Amy Maxmen
amaxmen@rockefeller.edu
Rockefeller University Press
Source:Eurekalert

Related biology news :

1. Turtles no longer turned into souvenirs
2. Inactivity of proteins behind longer shelf life when freezing
3. No longer a gray area: Our hair bleaches itself as we grow older
4. Shorter wait means longer life for kidney transplant candidates
5. Living longer thanks to the longevity gene
6. For fats, longer may not be better
7. Deprived of a sense of smell, worms live longer
8. Formula discovered for longer plant life
9. The mystery of mass extinctions is no longer murky
10. Mouse study: When it comes to living longer, its better to go hungry than go running
11. Antioxidant users dont live longer, analysis of studies concludes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
Breaking Biology News(10 mins):
(Date:7/24/2017)... Intralytix, Inc. announced that it received $17.5 million in ... This investment marks the beginning of a close collaboration ... for various benefits in human health and in other ... As a global key player in yeasts ... for baking, food taste & pleasure, health care, and ...
(Date:7/24/2017)... FL (PRWEB) , ... July ... ... Strategic Analyst, Kenny Soulstring, today announced that the stock market news outlet ... in risk assessment diagnostic testing that screens and identifies exposure, progression and ...
(Date:7/20/2017)... ... 2017 , ... Resoundant, Inc. is pleased to introduce ... U.S. that offer MR Elastography for liver fibrosis staging. MR Elastography is ... liver fibrosis assessment. , “MRE:connect was created in response to an increasing number ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... quality of life, today announced its full advisory board. The board comprises leaders ... promotion of James Crooks, PhD, former VP of Engineering, to Chief Technology Officer. ...
Breaking Biology Technology: